L12 ANSWER 7 OF 35 PCTFULL COPYRIGHT 2003 Univentio

ACCESSION NUMBER: 1998044129 PCTFULL ED 20020514

TITLE (ENGLISH): ENHANCEMENT OF IMMUNE RESPONSE USING TARGETING MOLECULES

TITLE (FRENCH): AMELIORATION DE LA REACTION IMMUNE AU MOYEN DE MOLECULES DE CIBLAGE

INVENTOR(S): BOYLE, Jefferey, Stephen; BRADY, Jamie, Louise; LEW, Andrew, Mark

PATENT ASSIGNEE(S): THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH; COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION; THE UNIVERSITY OF MELBOURNE;

THE

WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH; CSL LIMITED; BOYLE, Jefferey, Stephen; BRADY, Jamie, Louise; LEW, Andrew, Mark

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9844129	**A1**	**19981008**

DESIGNATED STATES: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

APPLICATION INFO.:	WO 1998-AU208	A	19980326
PRIORITY INFO.:	AU 1997-PO 5891		19970327
	AU 1998-PP 1830		19980213

PI **WO 9844129** **A1 19981008**

L12 ANSWER 22 OF 35 PCTFULL COPYRIGHT 2003 Univentio

ACCESSION NUMBER:	1995031483 PCTFULL ED 20020514
TITLE (ENGLISH):	IMPROVEMENTS IN OR RELATING TO PEPTIDE DELIVERY
TITLE (FRENCH):	ADMINISTRATION AMELIOREE DE PEPTIDES
INVENTOR(S):	CARDY, Donald, Leonard, Nicholas; CARR, Frank, Joseph
PATENT ASSIGNEE(S):	ECLAGEN LIMITED; CARDY, Donald, Leonard, Nicholas; CARR, Frank, Joseph
LANGUAGE OF PUBL.:	English
DOCUMENT TYPE:	Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9531483	**A1**	**19951123**
DESIGNATED STATES	AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA US UZ VN KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1995-GB1107	A	19950515
PRIORITY INFO.:	GB 1994-9409643.5		19940513
	GB 1994-9417461.2		19940831
PI	**WO 9531483**	**A1**	**19951123**

L12 ANSWER 28 OF 35 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 1993022332 PCTFULL ED 20020513
TITLE (ENGLISH): RECOMBINANT PRODUCTION OF IMMUNOGLOBULIN-LIKE DOMAINS IN PROKARYOTIC CELLS
TITLE (FRENCH): PRODUCTION RECOMBINANTE DE DOMAINES SEMBLABLES A L'IMMUNOGLOBULINE DANS DES CELLULES PROCARYOTES
INVENTOR(S): WARD, Elizabeth, Sally; KIM, Jin-Kyoo
PATENT ASSIGNEE(S): BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM; WARD,
Elizabeth, Sally; KIM, Jin-Kyoo
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9322332	**A2**	**19931111**
DESIGNATED STATES	AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US US VN AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1993-US3895	A	19930426
PRIORITY INFO.:	US 1992-7/873,930		19920424
	US 1992-7/963,333		19921019

PI **WO 9322332** **A2 19931111**
ABEN Disclosed are recombinant vectors encoding immunoglobulin-like domains and portions thereof,
such as T-cell variable domains, antidoby **Fc**-hinge fragments, subfragments and mutant domains with
reduced biological half lives. Methods of producing large quantities of such domains, heterodimers,
and. . . are single chain T-cell receptors, which are folded into beta-pleated sheet structures
similar to those of immunoglobulin variable domains; antibody **Fc** and **Fc**-hinge domains, which have
the same in vivo stability as intact antibodies; and domains engineered to have reduced in vivo half. . . and protein domains will be useful as templates for in vitro mutagenesis
and high resolution structural studies; for immunization and **vaccination**; and for the production of
recombinant antibodies or chimaeric proteins with increased or decreased
stability and longevity for
therapeutic and. . .
ABFR . . . a

intravenous

L12 ANSWER 34 OF 35 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 1989012458 PCTFULL ED 20020513
TITLE (ENGLISH): HETEROFUNCTIONAL CELLULAR IMMUNOLOGICAL REAGENTS, VACCINES CONTAINING SAME AND METHODS FOR THE USE OF SAME
TITLE (FRENCH): REACTIFS IMMUNOLOGIQUES CELLULAIRES HETEROFONCTIONNELS, VACCINS LES CONTENANT ET LEURS MODES D'UTILISATION
INVENTOR(S): ZIMMERMAN, Daniel, H.; ELLIOTT, Donald, A.
PATENT ASSIGNEE(S): CELL MED, INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 8912458	**A1**	**19891228**
DESIGNATED STATES	AT AU BE CH DE FR GB IT JP LU NL SE		
APPLICATION INFO.:	WO 1989-US2503	A	19890612
PRIORITY INFO.:	US 1988-206,381		19880614
PI	**WO 8912458**	**A1**	**19891228**

all mods

L12 ANSWER 23 OF 35 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 1995010302 PCTFULL ED 20020514
TITLE (ENGLISH): CELLULAR AND SERUM PROTEIN ANCHORS AND CONJUGATES
TITLE (FRENCH): PROTEINE SERIQUE ET CELLULAIRE D'ANCRAGE ET CONJUGUES
INVENTOR(S): POULETTY, Philippe; POULETTY, Christine
PATENT ASSIGNEE(S): REDCELL, INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9510302	**A1**	**19950420**

DESIGNATED STATES: AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
APPLICATION INFO.: WO 1994-US10547 A 19940916
PRIORITY INFO.: US 1993-8/137,821 19931015
US 1994-8/237,346 19940503

PI **WO 9510302** **A1 19950420**

ABEN . . . target in a mammalian host, such as a toxin, drug of abuse, microbe, autoreactive immune cell, infected or tumourous cell, **antigen presenting** cell, or the like, joined to a second binding member specific for along-lived blood component, including cells, such as an. . .

DETD . . . for cardiovascular diseases, immunoglobulins such as total IgE for anaphylaxy, specific anti-allergen IgE, auto or allo-antibodies for autoimmunity or allo- or xenoimmunity, Ig **Fc** receptors or **Fc** receptor binding f actors , carbohydrates (gal), natural antibodies involved in a'llo- or xenorejection, erythropoietin, angiogenesis factors, adhesion molecules, MIF, MAFj complement factors (classical. . . therapeutic dosage monitoring, treatments for overdosage of drugs or drugs of abuse, or the like. Also, the subject invention may be used to **vaccinate** against a pathogen or other deleterious entity, where various unicellular microorganisms and viruses have been described above. In addition, the subject invention can be employed to activate T cells toward particular targets, by providing for appropriate targets for **antigen presenting** cells, which will then present to the T cells or providing for direct activation of T cells The choice of the long-lived blood. . .

intramuscular
Sub-Q

L12 ANSWER 19 OF 35 PCTFULL COPYRIGHT 2003 Univentio

ACCESSION NUMBER: 1996040789 PCTFULL ED 20020514

TITLE (ENGLISH): THERAPEUTIC COMPOUNDS COMPRISED OF ANTI-Fc RECEPTOR ANTIBODIES

TITLE (FRENCH): COMPOSES THERAPEUTIQUES CONSTITUES D'ANTICORPS ANTI-RECEPTEURS FC

INVENTOR(S): DEO, Yashwant, M.; GOLDSTEIN, Joel; GRAZIANO, Robert; SOMASUNDARAM, Chezian

PATENT ASSIGNEE(S): MEDAREX, INC.

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9640789	**A1**	**19961219**

DESIGNATED STATES: AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

APPLICATION INFO.: WO 1996-US9988 A 19960607

PRIORITY INFO.: US 1995-8/484,172 19950607

PI **WO 9640789** **A1 19961219**

L12 ANSWER 18 OF 35 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 1997005886 PCTFULL ED 20020514
TITLE (ENGLISH): COMPOSITIONS FOR CONFERRING IMMUNOGENICITY TO A PEPTIDE
TITLE (FRENCH): COMPOSITIONS CONFERANT UNE IMMUNOGENICITE A UN PEPTIDE
INVENTOR(S): STANTON, G., John; HUGHES, Thomas, K., Jr.; SMITH, Eric, M.
PATENT ASSIGNEE(S): BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9705886	**A1**	**19970220**

DESIGNATED STATES: AU CA JP AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE
APPLICATION INFO.: WO 1996-US12632 A 19960805
PRIORITY INFO.: US 1995-8/511,662 19950804
PI **WO 9705886** **A1 19970220**

DETD

Sub Q ; intramuscular

L14 ANSWER 1 OF 26 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 1999028349 PCTFULL ED 20020515
TITLE (ENGLISH): CELLS EXPRESSING ANTI-Fc RECEPTOR BINDING COMPONENTS
TITLE (FRENCH): CELLULES EXPRIMANT DES COMPOSANTS DE FIXANT AU RECEPTEUR ANTI Fc
INVENTOR(S): KELER, Tibor; GOLDSTEIN, Joel; GRAZIANO, Robert; DEO, Yashwant, M.
PATENT ASSIGNEE(S): MEDAREX, INC.; KELER, Tibor; GOLDSTEIN, Joel; GRAZIANO, Robert; DEO, Yashwant, M.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9928349	**A2**	**19990610**

DESIGNATED STATES: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 1998-US25556	A	19981202
PRIORITY INFO.:	US 1997-60/067,232		19971202

PI **WO 9928349** **A2 19990610**

L14 ANSWER 10 OF 26 PCTFULL COPYRIGHT 2003 Univentio

ACCESSION NUMBER: 1998002463 PCTFULL ED 20020514

TITLE (ENGLISH): THERAPEUTIC MULTISPECIFIC COMPOUNDS COMPRISED OF ANTI-FC'alpha' RECEPTOR ANTIBODIES

TITLE (FRENCH): COMPOSES THERAPEUTIQUES A SPECIFICITE MULTIPLE CONSISTANT EN ANTICORPS ANTI-RECEPTEURS DU FC'alpha'

INVENTOR(S): DEO, Yashwant, M.; GRAZIANO, Robert; KELER, Tibor

PATENT ASSIGNEE(S): MEDAREX, INC.; DEO, Yashwant, M.; GRAZIANO, Robert; KELER, Tibor

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9802463	**A1**	**19980122**

DESIGNATED STATES: AL AM AT AU AZ BA BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

APPLICATION INFO.: WO 1997-US12013 A 19970710

PRIORITY INFO.: US 1996-8/678,194 19960711

PI **WO 9802463** **A1 19980122**

L12 ANSWER 8 OF 35 PCTFULL COPYRIGHT 2003 Univentio

ACCESSION NUMBER: 1998035684 PCTFULL ED 20020514

TITLE (ENGLISH): METHODS FOR DETECTION OF KAPOSI'S SARCOMA-ASSOCIATED HERPESVIRUS-LIKE VIRUS

TITLE (FRENCH): METHODES DE DETECTION D'UN VIRUS SEMBLABLE A L'HERPESVIRUS ASSOCIE AU SARCOME DE KAPOSI

INVENTOR(S): BERENSON, James, R.; RETTIG, Matthew, B.; VESCIO, Robert, A.

PATENT ASSIGNEE(S): BERENSON, James, R.; RETTIG, Matthew, B.; VESCIO, Robert, A.

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9835684	**A2**	**19980820**

DESIGNATED STATES: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

APPLICATION INFO.: WO 1998-US2820 A 19980212

PRIORITY INFO.: US 1997-8/800,710 19970214

US 1997-8/967,504 19971111

PI **WO 9835684** **A2 19980820**

I. V.

L12 ANSWER 16 OF 35 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 1997030089 PCTFULL ED 20020514
TITLE (ENGLISH): NOVEL ANTIBODY-CYTOKINE FUSION PROTEIN, AND METHODS OF MAKING AND USING THE SAME
TITLE (FRENCH): NOUVELLE PROTEINE DE FUSION ANTICORPS-CYTOKINE ET METHODES D'ELABORATION ET D'UTILISATION DE CETTE PROTEINE
INVENTOR(S): HARVILL, Eric, T.; MORRISON, Sherie, L.
PATENT ASSIGNEE(S): HARVILL, Eric, T.; MORRISON, Sherie, L.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9730089	**A1**	**19970821**
DESIGNATED STATES	AU CA IL JP US AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE		
APPLICATION INFO.:	WO 1997-US1420	A	19970211
PRIORITY INFO.:	US 1996-60/011,569		19960213
PI **WO 9730089**	**A1 19970821**		

L12 ANSWER 12 OF 35 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 1998006749 PCTFULL ED 20020514
TITLE (ENGLISH): SOLUBLE MONOVALENT AND MULTIVALENT MHC CLASS II FUSION PROTEINS, AND USES THEREFOR
TITLE (FRENCH): PROTEINES DE FUSION DE CLASSE II DU CMH, SOLUBLES, MONOVALENTES OU POLYVALENTES, ET UTILISATIONS

ASSOCIEES
INVENTOR(S): WUCHERPFENNIG, Kai, W.; STROMINGER, Jack, L.
PATENT ASSIGNEE(S): PRESIDENT AND FELLOWS OF HARVARD COLLEGE; WUCHERPFENNIG, Kai, W.; STROMINGER, Jack, L.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9806749	**A2**	**19980219**
DESIGNATED STATES	AU CA JP NZ US AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE		
APPLICATION INFO.:	WO 1997-US14503	A	19970815
PRIORITY INFO.:	US 1996-60/024,077		19960816
PI	**WO 9806749**	**A2**	**19980219**

DETD . . . responses by binding peptides from foreign antigens in an intracellular
processing compartment, and by presenting these peptides on the surface of **antigen presenting**
cells, where they may be recognized by specialized T cell receptors (TCRs) (reviewed in
Strominger and Wiley, 1995). For example, the MHC. . .
. . .
0 chain. MHC class 11 molecules bind peptides
in an intracellular processing compartment and present these peptides on
the surface of **antigen**
presenting cells to T cells. Peptides are bound in an extended conformation, as left-handed type 11
polyproline helices, The majority of bound. . .
. . .
or to tolerize an individual to a particular MHC-peptide complex. For example, the
Class II MHC fusion proteins may be include **Fc** regions which activate the complement system
and, thereby, cause the destruction of T cells to which they bind, Alternatively, the fusion
proteins. . . other point which does not interfere with the binding of the NMC-peptide
complex to T cell receptors (e.g., anywhere along an **Fc** domain). Such cytotoxic substances
include, for example, genistein, ricin, diphtheria toxins, Pseudomonas toxins, and radioactive
I 0 isotopes (e.g., 1211). High doses. . . 11 N4HC fusion protein of the invention can
cause tolerization to the NMC-peptide complex, even when lower doses would cause
sensitization (i.e., **vaccination** or immunization). When the goal is to tolerize an individual to an
antigen which is normally presented by the subject's own. . .

L12 ANSWER 3 OF 35 PCTFULL COPYRIGHT 2003 Univentio

ACCESSION NUMBER: 1999013095 PCTFULL ED 20020515

TITLE (ENGLISH): USE OF MULTIVALENT CHIMERIC PEPTIDE-LOADED, MHC/IG MOLECULES TO DETECT, ACTIVATE OR SUPPRESS ANTIGEN-SPECIFIC T CELL-DEPENDENT IMMUNE RESPONSES

TITLE (FRENCH): UTILISATION DE MOLECULES POLYVALENTES DU TYPE COMPLEXE MAJEUR D'HISTOCOMPATIBILITE (CMH)/IMMOGLOBULINE (IG) CHARGEES EN PEPTIDES CHIMERES POUR DECELER, ACTIVER OU SUPPRIMER LES REPONSES IMMUNES DEPENDANT DES CELLULES T SPECIFIQUES DE L'ANTIGENE

INVENTOR(S): SCHNECK, Jonathan; PARDOLL, Drew; O'HERRIN, Sean, M.; SLANSKY, Jill; GRETEN, Tim

PATENT ASSIGNEE(S): THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE; SCHNECK, Jonathan; PARDOLL, Drew; O'HERRIN, Sean, M.; SLANSKY, Jill; GRETEN, Tim

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9913095	**A2**	**19990318**

DESIGNATED STATES: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 1998-US18909	A	19980911
PRIORITY INFO.:	US 1997-60/058,573		19970911
	US 1998-60/082,538		19980421

PI **WO 9913095** **A2 19990318**

L12 ANSWER 5 OF 35 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 1998047916 PCTFULL ED 20020514
TITLE (ENGLISH): BIFUNCTIONAL POLYPEPTIDES FOR CELL-SPECIFIC VIRAL TARGETING
TITLE (FRENCH): POLYPEPTIDES BIFONCTIONNELS UTILISES DANS LE CIBLAGE VIRAL SPECIFIQUE EN FONCTION DES CELLULES
INVENTOR(S): YOUNG, John; SNITKOVSKY, Sophie
PATENT ASSIGNEE(S): PRESIDENT AND FELLOWS OF HARVARD COLLEGE; YOUNG, John; SNITKOVSKY, Sophie
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9847916	**A1**	**19981029**
DESIGNATED STATES	AU CA JP NZ US AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE		
APPLICATION INFO.:	WO 1998-US7720	A	19980416
PRIORITY INFO.:	US 1997-08/844,359		19970418
PI	**WO 9847916**	**A1**	**19981029**

DETD . . . epithelial cell, fibroblast, smooth muscle cell, blood cell (including a hematopoietic cell, red blood cell, T-cell, B-cell, etc.), tumor cell, cardiac muscle cell, macrophage, **dendritic** cell, neuronal cell (e.g., a glial cell or astrocyte), or pathogen-infected cell (e.g., those infected by bacteria, viruses, virusoids, parasites, or prions).

. . . exist in the virus 5 as it is found in nature. Examples of therapeutic proteins include antigens or immunogens such as a polyvalent **vaccine**, cytokines, tumor necrosis factor, interferons, interleukins, adenosine deaminase, insulin, T-cell receptors, soluble CD4, epidermal growth factor, human growth factor, blood factors, such as. . . ApoC, ApoAI, the LDL receptor, negative selection markers or suicide proteins, such as thymidine kinase (including the HSV, CMV, VZV TK), anti-angiogenic factors, **Fc** receptors, plasminogen activators, such as t-PA, u-PA and streptokinase, dopamine, MHC, tumor suppressor genes such as p53 and Rb, monoclonal antibodies or antigen binding. . .

CLMEN. . . the target cell is selected from the group consisting of epithelial cells, fibroblasts, smooth muscle cells, blood cells, tumor cells, cardiac muscle cells, macrophages, **dendritic** cells, neuronal cells, and pathogen-infected cells.

L12 ANSWER 25 OF 35 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 1995000175 PCTFULL ED 20020514
TITLE (ENGLISH): AGENT WITH INFLUENCES HYPERACTIVE IMMUNOLOGICAL EFFECTOR CELLS
TITLE (FRENCH): AGENT PERMETTANT D'INFLUER SUR DES CELLULES EFFECTRICES
IMMUNOLOGIQUES HYPERACTIVEES
INVENTOR(S): LESKOVAR, Peter
PATENT ASSIGNEE(S): LESKOVAR, Peter
LANGUAGE OF PUBL.: German
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9500175	**A1**	**19950105**

DESIGNATED STATES: US AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
APPLICATION INFO.: WO 1994-EP1992 A 19940619
PRIORITY INFO.: DE 1993-P 43 20 878.9 19930623
DE 1993-P 43 24 877.2 19930725
DE 1994-P 44 11 956.9 19940407
PI **WO 9500175** **A1 19950105**

DETD Der fUer die Transplantat-Abstossung kritische Anstieg der HHC II-positiven **APCs** (11passenger lymphocytes) in organtransplantat kann durch Zusatz von Anti-HLAe-DR-Hab bzw. entsprechende Fab/F(abl)2-Untereinheit und/oder Ca-Kanalblocker (Verapatil, Nifedipin, Dilthiazem) verhindert werden,
Eine weitere Verbesserung. . .
. . .
Complement-Faktor)-Assoziat treten; hierdurch werden in vivo die Nakrophagen des Impflings noch stAerker vor den Suppressor-T-Zellen bevorzugt, weil das Assoziat durch **Fc**- und C-Rezeptoren auf Nakrophagen gebunden wird,
(3) Zur weiteren VerstAerkung der Immunisierung durch **Vaccinepathogen** wird der Zusatz von Pathogen-spezifischen IgE und/oder Konjugaten aus Pathogen-spezifischen Fab/F(abl)2-Untereinheit von IgG/IgM plus **Fc**-Fragment von (IgE beliebiger SpezifitAet) allein oder kombiniert mit IL-4 empfohlen,
(4) Es ist ratsam die erste Impfung (priting) mit Zusatz von. . .